Evidence map›Paper›PMID 30150378›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Florian A Siebzehnrübl, Kerstin A Raber, Yvonne K Urbach, Anja Schulze-Krebs, Fabio Canneva, Sandra Moceri, Johanna Habermeyer, Dalila Achoui, Bhavana Gupta, Dennis A Steindler and 21 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. The role of histone deacetylase 3 in breast cancer.Medical oncology (Northwood, London, England) · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 14 institutions in 7 countries.

Florian A SiebzehnrüblMcKnight Brain Institute, Department of Neurosurgery, University of Florida, Gainesville, FL 32611.ORCID 0000-0001-8411-8775
Kerstin A RaberDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Yvonne K UrbachDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Anja Schulze-KrebsDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Fabio CannevaDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Sandra MoceriDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Johanna HabermeyerDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany.
Dalila AchouiMcKnight Brain Institute, Department of Neurosurgery, University of Florida, Gainesville, FL 32611.
Bhavana GuptaEuropean Cancer Stem Cell Research Institute, Cardiff University School of Biosciences, Cardiff CF10 3AX, United Kingdom.
Dennis A SteindlerMcKnight Brain Institute, Department of Neurosurgery, University of Florida, Gainesville, FL 32611.
Michael StephanClinic of Psychosomatic and Psychotherapy, Medical School Hannover, 30625 Hannover, Germany.
Huu Phuc NguyenInstitute of Medical Genetics and Applied Genomics, Center for Rare Diseases, University of Tübingen, 72074 Tübingen, Germany.
Michael BoninInstitute of Medical Genetics and Applied Genomics, Center for Rare Diseases, University of Tübingen, 72074 Tübingen, Germany.
Olaf RiessInstitute of Medical Genetics and Applied Genomics, Center for Rare Diseases, University of Tübingen, 72074 Tübingen, Germany.
Andreas BauerInstitute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425 Jülich, Germany.
Ludwig AignerInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, 5020 Salzburg, Austria.
Sebastien Couillard-DespresInstitute of Experimental Neuroregeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0002-8486-6412
Martin Arce PaucarSection of Translational Neuropharmacology, Department of Physiology and Pharmacology, Karolinska Institute, 171 77 Solna, Sweden.
Per SvenningssonSection of Translational Neuropharmacology, Department of Physiology and Pharmacology, Karolinska Institute, 171 77 Solna, Sweden.
Alexander OsmandDepartment of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996.
Alexander AndreewInstitute for Human Genetics, Charité-Universitätsmedizin, 13353 Berlin, Germany.
Claus ZabelInstitute for Human Genetics, Charité-Universitätsmedizin, 13353 Berlin, Germany.
Andreas WeissNeuroscience Discovery, Novartis Pharma AG, 4056 Basel, Switzerland.
Rainer KuhnNeuroscience Discovery, Novartis Pharma AG, 4056 Basel, Switzerland.
Saliha MoussaouiNeuroscience Discovery, Novartis Pharma AG, 4056 Basel, Switzerland.
Ines BlockxBio-Imaging Laboratory, University of Antwerp, 2000 Antwerp, Belgium.
Annemie Van der LindenBio-Imaging Laboratory, University of Antwerp, 2000 Antwerp, Belgium.
Rachel Y CheongTranslational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden.
Laurent RoybonStem Cell Laboratory for CNS Disease Modeling, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden.
Åsa PetersénTranslational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden.
Stephan von HörstenDepartment of Experimental Therapy, Friedrich-Alexander-University, 91054 Erlangen, Germany; stephan.v.hoersten@fau.de.ORCID 0000-0001-6409-0664
Friedrich-Alexander-Universität Erlangen-Nürnberg · DELund University · SENovartis (Switzerland) · CHUniversity of Tübingen · DECharité - Universitätsmedizin Berlin · DEKarolinska Institutet · SEParacelsus Medical University · ATUniversity of Antwerp · BEUniversity of Florida · USCardiff University · GBForschungszentrum Jülich · DEMedizinische Hochschule Hannover · DETufts University · USUniversity of Tennessee at Knoxville · US

Funding

STEM/PROGENITOR CELL PROTECTION FOR PARKINSON'S DISEASER01NS055165 · NINDS · UNIVERSITY OF FLORIDA · PI STEINDLER, DENNIS A. · 2007 to 2011
$1.6M
NINDS NIH HHS R01 NS055165
6 · The paper itself

Abstract

Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by expanded CAG repeats in the

Indexed as

AnimalsAnimals, Genetically ModifiedCell DifferentiationDisease Models, AnimalFemaleHistone Deacetylase InhibitorsHumansHuntingtin ProteinHuntington DiseaseHydroxamic AcidsIndolesLateral VentriclesMaleMice, TransgenicMutationNeuronsHistone Deacetylase InhibitorsHTT protein, humanHuntingtin ProteinHydroxamic AcidsIndolesPanobinostatanimal modeldevelopmentexperimental therapymultiomicsneurodegeneration

Identifiers

PMID30150378
PMCPMC6140493
OpenAlexW2889060107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.